62nd ASH Annual Meeting and Exposition: 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Poster II

Oral and Poster Abstracts
Poster

AML, antibodies, apoptosis, Biological, Animal models, Diseases, Lymphoma (any), Non-Biological, cell regulation, chemical interactions, Combinations, Mantle Cell Lymphoma, Therapies, checkpoint inhibitors, chemotherapy, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Biological Processes, DLBCL, DNA damage, enzyme inhibitors, white blood cells, Technology and Procedures, Cell Lineage, immunotherapy, Xenograft models, Lymphoid Malignancies, Study Population, Clinically relevant, Myeloid Malignancies, pharmacology, immune mechanism, molecular interactions

2087

Macrophage Activation By Dual PI3K-δ/γ Inhibition Enhances Anti-CD47-Mediated Phagocytosis and Prolongs Survival in DLBCL

James Godfrey, MD¹, Wenjun Kang, MS²^*, Lei Huang, PhD²^*, Silvia Coma, PhD³^*, Roy Maute, PhD⁴^*, Mark P. Chao, MD, PhD⁴^*, Jonathan A Pachter, PhD³, Sonali Smith, MD²^* and Justin Kline, MD¹

¹Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL
²University of Chicago, Chicago, IL
³Verastem, Needham, MA
⁴Gilead Sciences, Inc., Foster City, CA

2088

Ktx-120, a Novel Irakimid Degrader of IRAK4 and IMiD Substrates Shows Preferential Activity and Induces Regressions in MYD88-Mutant DLBCL CDX and PDX Models

Duncan Walker, PhD¹, Michele Mayo²^*, Christine Klaus, BS²^*, Dapeng Chen, PhD²^*, Samyabrata Bhaduri, PhD²^*, Kirti Sharma²^*, Scott Rusin²^*, Alice McDonald, PhD²^*, Jared Gollob, PhD, MD²^*, Nello Mainolfi, PhD²^* and Matt Weiss, PhD²^*

¹Kymera Therapeutics, Cambridge, MA
²Kymera Therapeutics, Watertown, MA

2089

SGN-CD30C, an Investigational CD30-Directed Camptothecin Antibody-Drug Conjugate (ADC), Shows Strong Anti Tumor Activity and Superior Tolerability in Preclinical Studies

Maureen Ryan^*, Ryan Lyski^*, Lauren Bou^*, Ryan Heiser^*, Bryan Grogan^*, Dave Meyer^*, Steven Jin^*, Jessica Simmons^*, Melissa Conerly^*, Peter Senter, PhD^* and Scott Jeffrey^*

Seattle Genetics, Inc., Bothell, WA

2090

Mechanisms of the Anti-Tumor Activity of STAT3 Degraders in Lymphoma

Haojing Rong, PhD¹^*, Kirti Sharma¹^*, Fred Csibi¹^*, Bin Yang¹^*, Scott Rusin¹^*, Yatao Shi, PhD¹^*, Joyoti Dey, PhD¹^*, Rahul Karnik¹^*, Michele Mayo¹^*, Karen Yuan¹^*, Yogesh Chutake¹^*, Alice McDonald, PhD¹^*, Sean Zhu, PhD¹^*, Nan Ji, PhD¹^*, Phillip Liu, PhD¹^*, Henry Li, PhD¹^*, Duncan Walker, PhD², Jared Gollob, PhD, MD¹^*, Nello Mainolfi, PhD¹^* and Chris Desavi¹^*

¹Kymera Therapeutics, Watertown, MA
²Kymera Therapeutics, Cambridge, MA

2091

Discovery of JNJ-67856633: A Novel, First-in-Class MALT1 Protease Inhibitor for the Treatment of B Cell Lymphomas

Ulrike Philippar, PhD¹, Ricardo M. Attar, PhD², Tianbao Lu³^*, Lorena Fontan, PhD⁴, Nele Vloemans¹^*, Mariette Bekkers¹^*, Luc Van Nuffel¹^*, Marcello Gaudiano⁵^*, Katarzyna Wnuk-Lipinska, PhD⁵^*, Bas-jan Van Der Leede¹^*, Katie Amssoms¹^*, Kristof Kimpe¹^*, Bart Medaer¹^*, Tony Greway³^*, Yann Abraham, PhD⁶^*, Max Cummings³^*, Emanuele Trella¹^*, Greet Vanhoof¹^*, Weimei Sun⁷^*, Jan Willem Thuring¹^*, Peter Connolly³^*, Joannes Linders, PhD¹^*, Haopeng Rui⁸^*, Sriram Balasubramanian⁹, John Gerecitano, MD, PhD¹⁰, Jenna D. Goldberg, MD¹¹^*, Ari Melnick, MD¹², Yusri A Elsayed, MD, PhD¹³^*, Jennifer Smit¹¹^*, Jacqueline Bussolari, PhD¹⁴ and James P Edwards¹⁵^*

¹Janssen Research & Development, Beerse, Belgium
²Janssen Research & Development, L.L.C., Spring House, PA
³Janssen Research & Development, Springhouse
⁴Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Long Island City, NY
⁵Janssen Research & Development, Beerse, BEL
⁶Computational Sciences, Janssen R&D, Beerse, Belgium
⁷Johnson & Johnson PRD, Spring House, PA
⁸Janssen Research & Development, Shanghai, China
⁹Janssen R&D, La Jolla, CA
¹⁰The Janssen Pharmaceutical Companies of Johnson & Johnson, West New York, NJ
¹¹Janssen R&D, Raritan, NJ
¹²Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY
¹³Janssen R&D, Spring House, PA
¹⁴Janssen Research & Development, LLC, Raritan, NJ
¹⁵Janssen Research & Development, La Jolla

2092

R-Nanochop Incorporating a TFR1-Targeted Doxorubicin Nanocarrier Is Superior to R-CHOP in a PDX Model of Diffuse Large B-Cell Lymphoma

Artavazd Arumov, BSc^1,2, Piumi Y. Liyanage, PhD³^*, Asaad Trabolsi, MD^2,4^*, Evan R. Roberts, BS²^*, Braulio C. L. B. Ferreira, BS³^*, Austin D. Newsam, BS²^*, Daniel Bilbao, PhD², Roger M. Leblanc, PhD³^* and Jonathan H. Schatz, MD^2,5

¹Sheila and David Fuente Graduate Program in Cancer Biology, University of Miami Miller School of Medicine, Miami, FL
²Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL
³Department of Chemistry, University of Miami, Coral Gables, FL
⁴Division of Hospital Medicine, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL
⁵Division of Hematology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL

2093

The Anti-Tumor Activity of Igm-8444, an Agonistic Death Receptor 5 (DR5) IgM Antibody, Is Sensitized in Combination with Chemotherapy and Bcl-2 Inhibitors in NHL and AML

Beatrice T. Wang, PhD^*, Thomas J. Matthew, PhD^*, Ling Wang, MS^*, Tasnim Kothambawala^*, Susan E. Calhoun, MS^*, Eric W. Humke, MD^*, Angus M. Sinclair, PhD and Bruce A. Keyt, PhD

IGM Biosciences Inc, Mountain View, CA

2094

AZD4320 Is a Novel and Potent BCL-2/X_L Dual Inhibitor in Targeting Aggressive Mantle Cell Lymphoma

Yijing Li, MS¹^*, Yang Liu, PhD¹^*, Joseph McIntosh, BS¹^*, Alexa A Jordan, BS¹^*, Angela Leeming¹^*, Courtney L Andersen, PhD²^*, Justin Cidado, PhD²^*, Vivian Changying Jiang, PhD¹ and Michael Wang, MD^1,3

¹Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
²Oncology R&D, AstraZeneca, Waltham, MA
³Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

2095

The Combination of Tafasitamab and Rituximab Increases Cytotoxicity Against Lymphoma Cells In Vitro

Maria Patra^*, Christian Augsberger^*, Carmen Ginzel^*, Andrea Polzer^*, Karin Landgraf^*, Dominik Bartel^*, Daniel Ness^*, Stefan Steidl^*, Christina Heitmüller^*, Juergen Schanzer^* and Jan Endell^*

MorphoSys AG, Planegg, Germany

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH